SAMIRNA
Live / Registered — Registered — partial Section 8 accepted (as of 05 Oct 2022)
What this means for you
Registered since 04 Oct 2016. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 86287682
- Registration number
- 5052167
- Mark type
- Stylized text
- Filed
- 21 May 2014
- Published for opposition
- 19 Jul 2016
- Registered
- 04 Oct 2016
- Attorney of record
- Jun-Hwa Jeong
Goods and services
- Class 001 — Chemicals: Diagnostic preparations for research use; Reagents for scientific research use; Chemicals for laboratory analyses, other than for medical use, namely, chemicals for use in biotechnological product development; Chemicals for pharmaceutical purposes, namely, for use in the manufacture of drugs and medicines; Chemicals for the manufacture of medical products in the nature of pharmaceutical preparations; Biochemicals, namely, biochemical reagents used for non-medical purposes; Chemical preparations for the manufacture of medical products
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Biological preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Medicated vaccines and serums for treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Capsules sold empty for pharmaceutical purposes for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Microspheres containing pharmaceutical preparations, for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Preparations and substances for facilitating delivery of pharmaceutical preparations, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Carriers for drug delivery, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Peptides for drug delivery, namely, drug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; Pharmaceutical preparations applied pharmaceutical drug delivery system, namely, elixirs for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies and a nanoparticle carrier for transferring siRNA in the cell or peptide; Chemical reagents for medical use; Pharmaceutical preparations for drug delivery into cells; Drug delivery formulations, namely, compositions consisting of nanoparticle for transferring siRNA in the cell or peptides; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purpose; Pharmaceutical preparations and substances for facilitating drug delivery in the form of nanoparticle for transferring siRNA in the cell or peptide for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing RNA for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing DNA for use in medical treatment via inhibition of gene expression
- Class 010 — Medical apparatus: [ Drug delivery system; Implantable drug syringes for drug delivery devices; Implantable drug delivery pumps for drug delivery devices; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Injection device for pharmaceuticals; Microspheres, namely, unilaminar and bilaminar spherical particles comprising hydrophilic and hydrophobic polymers with diameters in the nanometer range used as a means for drug delivery for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies ]
- Class 042 — Scientific and technological services: Pharmaceutical products research; Pharmaceutical products development; Research for medical products; Crude medicines research; Research and development of biotechnology for others; Quality control, namely, quality control of target gene expression activity with siRNA; Biotechnology research
Owner
- BIONEER CORPORATION, Daejeon, KR
- BIONEER CORPORATION, Daejeon, 306-220, KR
- BIONEER CORPORATION, Daejeon, 306-220, KR
Prosecution history
- 04 Oct 2025 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 05 Oct 2022 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 05 Oct 2022 — REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
- 04 Oct 2022 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 26 Apr 2022 — TEAS SECTION 8 RECEIVED
- 04 Oct 2021 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 04 Oct 2016 — REGISTERED-PRINCIPAL REGISTER
- 19 Jul 2016 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Jul 2016 — PUBLISHED FOR OPPOSITION
- 29 Jun 2016 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Jun 2016 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 08 Jun 2016 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 Jun 2016 — EXAMINER'S AMENDMENT ENTERED
- 08 Jun 2016 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 08 Jun 2016 — EXAMINERS AMENDMENT E-MAILED